Abstract
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
MeSH terms
-
Aged
-
Carcinoma, Hepatocellular / complications
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / pathology
-
Humans
-
Liver Neoplasms / complications
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / pathology
-
Male
-
Niacinamide / analogs & derivatives*
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / therapeutic use*
-
Portal Vein / drug effects*
-
Portal Vein / pathology
-
Protein Kinase Inhibitors / therapeutic use*
-
Remission Induction
-
Sorafenib
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
Venous Thrombosis / complications
-
Venous Thrombosis / drug therapy*
-
Venous Thrombosis / pathology
Substances
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Niacinamide
-
Sorafenib